Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01012648
Recruitment Status : Unknown
Verified March 2011 by University of Zurich.
Recruitment status was:  Recruiting
First Posted : November 13, 2009
Last Update Posted : March 16, 2011
Information provided by:
University of Zurich

October 29, 2009
November 13, 2009
March 16, 2011
November 2009
January 2013   (Final data collection date for primary outcome measure)
Reduced amount of fluids given [ Time Frame: 3 days ]
Reduced amount of fluids given
Complete list of historical versions of study NCT01012648 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury
Not Provided

RCT colloids versus cristalloids only in severe burn victims.

  • Trial with medicinal product
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Drug: Fluid resuscitation
    Volume resuscitation
  • Drug: HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
    Volume Resuscitation
Not Provided
Béchir M, Puhan MA, Fasshauer M, Schuepbach RA, Stocker R, Neff TA. Early fluid resuscitation with hydroxyethyl starch 130/0.4 (6%) in severe burn injury: a randomized, controlled, double-blind clinical trial. Crit Care. 2013 Dec 23;17(6):R299. doi: 10.1186/cc13168.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Deep burn injury more than 15% of total body surface area (2nd and 3rd degree burns)
  • Informed consent (via deferred consent, if necessary, according to Swiss HMG § 55 and 56).
  • Patients or relatives can understand the study information and the provided information in German language

Exclusion criteria:

  • Patients expected to succumb within the next 24 to 36 hours, i.e. whole body burn trauma, palliative care situation
  • Pregnancy
  • No informed consent
  • Known allergic reaction to HES
  • Patients or patient's relatives, who do not understand the German language and therefore the study information, can not be provided in a legally correct manner.
  • Patients with contraindications for balanced 6% HES 130/0.4, i.e. heart failure, pulmonary edema, intracerebral bleeding, acute renal failure, severe hypernatraemia and other severe electrolyte imbalances, severe von-Willebrand Syndrome and acute liver failure (see "Arzneimittelkompendium der Schweiz® - Documed")
Sexes Eligible for Study: All
16 Years and older   (Child, Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Béchir Markus, MD, Intensivmedizin
University of Zurich
Not Provided
Principal Investigator: Markus Béchir, M.D: UniversitaetsSpital Zuerich
University of Zurich
March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP